Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States

Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States

MUMBAI, India and NAPLES, Fla., Aug. 10, 2026 /PRNewswire/ — Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet. The U.S. FDA has approved Lupin’s Sodium Zirc…

Lupin gets US FDA nod for sodium zirconium cyclosilicate

Lupin has received approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet, the company announced. The US FDA has approved Lupin’s Sodium Zirconium Cyclosilicate for Oral Suspension, 5 g/packet and 10 g/packet as bioequivalent to the reference listed drug (RLD) Lokelma for Oral Suspension of AstraZeneca Pharmaceuticals L…